Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time.
2024年6月3日，波士頓，(環球新聞社)——Entrada Therapeutics，Inc. (納斯達克: TRDA)是一家臨床階段的生物製藥公司，旨在通過建立一種新的藥物類別來影響細胞內長期被認爲無法接近的靶標，從而改變患者的生活。該公司今天宣佈，首席執行官Dipal Doshi將在高盛第45屆全球醫療保健會議上參加一個點火聊天。點火聊天將於2024年6月10日星期一東部時間下午4:00舉行。th現場網絡直播將在公司網站的投資者關係部分提供。在活動結束後的90天內，Entrada網站上將提供重播。
A live webcast will be available on the Investor Relations section of the Company's website at . A replay will be available on the Entrada website for 90 days following the event.
關於Entrada Therapeutics Entrada Therapeutics是一家臨床階段的生物製藥公司，旨在通過建立一種新的藥物類別來影響細胞內長期被認爲無法接近的靶標，從而改變患者的生活。該公司的內體溶酶體逃逸載體(EEV)-藥物是設計用於實現各種活性成分高效的胞內遞送到各種器官和組織，從而提高治療指標。通過這種獨有的、多功能的、模塊化的方法，Entrada正在推進一個強大的開發組合，包括基於RNA、抗體和酶的項目，潛在地治療神經肌肉、眼科、代謝和免疫性疾病等。該公司的先導寡核苷酸項目正在開發中，用於治療患有Duchenne肌萎縮症的人，這些人可進行exon 44、45和50的跳躍適應症。Entrada已與治療肌萎縮性側索硬化症1型的臨床階段項目VX-670合作。
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of active moieties into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company's lead oligonucleotide programs are in development for the treatment of people living with Duchenne muscular dystrophy who are exon 44, 45 and 50 skipping amenable. Entrada has partnered VX-670, a clinical-stage program for the treatment of myotonic dystrophy type 1.
有關Entrada Therapeutics的更多信息，請訪問我們的網站。請關注我們的LinkedIn。
Entrada Therapeutics是一家臨床階段的生物製藥公司，旨在通過建立一種新型藥物類別來改善患者的生活，這種藥物可以從長期以來被認爲無法進入的細胞內靶點入手。該公司的內體逃逸載體（EEV）療法旨在實現對各種器官和組織中廣泛活性物質的高效細胞內輸送，從而實現改善治療指數。通過這種專有的、多功能和模塊化的方法，Entrada正在推進一套堅實的發展組合，包括基於RNA、抗體和酶的計劃，用於潛在地治療神經肌肉、眼部、代謝和免疫疾病等多種疾病。該公司的主導寡核苷酸計劃正在開發中，用於治療患有Duchenne肌萎縮症的人，這些人具有外顯子44、45和50的跳躍易感性。Entrada已經與VX-670合作，這是一項治療肌無力症1型的臨床階段計劃。
For more information about Entrada, please visit our website, , and follow us on LinkedIn.
投資者和媒體聯繫 Caileigh Dougherty 投資者關係和企業溝通主管 cdougherty@entradatx.com
Investor and Media Contact
Caileigh Dougherty
Head of Investor Relations and Corporate Communications
cdougherty@entradatx.com
投資者和媒體聯繫人
投資者和媒體聯繫
Caileigh Dougherty
投資者關係和企業溝通主管
cdougherty@entradatx.com
譯文內容由第三人軟體翻譯。